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The central nervous system (CNS) actions of several hormones, including insulin, regulate metabolism in the liver and other
peripheral tissues. Inoue et al. (2006) have now identified an IL-6/STAT3-dependent pathway in the liver that mediates
a portion of the hepatic metabolic response to CNS insulin.Insulin is secreted by the b cells of the
pancreatic islets in response to feeding
and promotes the uptake and storage of
nutrients in insulin receptor-expressing
tissues such as the liver, skeletal muscle,
and adipose. In adipose tissue, insulin
stimulates the uptake of glucose and
lipids for storage as triglyceride, while in
muscle, insulin promotes the synthesis
of glycogen and protein. In liver, which
is responsible for the minute-by-minute
regulation of blood glucose levels and
can export glucose as well as store it, in-
sulin not only promotes the storage of
glucose as glycogen and the synthesis
of lipids but also inhibits the production
of sugar for export by gluconeogenesis
and glycogenolysis.
In addition to these direct effects of in-
sulin on glucose disposal in tissues such
as the liver, it has become clear that the
brain participates in the regulation of he-
patic glucose production and insulin re-
sponsiveness by sensing and responding
to nutrient levels (e.g., fatty acids; FAs)
(Lam et al., 2005) and hormonal signals
of energy intake and storage (e.g., insulin
and leptin) (Porte et al., 2005; Liu et al.,
1998; Obici et al., 2002; Kamohara et al.,
1997). A large and growing body of data
indicates that insulin acts within the CNS
to participate in the regulation of glucose
homeostasis in animals. Intracerebroven-
tricular (ICV) injection of insulin or insulin
receptor agonists suppresses hepatic
glucose production via an autonomic ner-
vous system-mediated inhibition of glu-
coneogenesis (Obici et al., 2002). Further-
more, inhibition of CNS insulin action by
disruption of brain insulin receptor ex-
pression results in increased glucose
production by the liver. Thus, while the
relative contributions of CNS and direct
hepatic insulin action in glycemic control
remain the topic of some discussion
(Edgerton et al., 2006), CNS insulin action
does contribute to the regulation of he-
patic glucose output. Our understanding
of the hepatic mechanisms underlying
these effects of CNS insulin is advanced
bywork published in this issue ofCell Me-
tabolism (Inoue et al., 2006); their dataCELL METABOLISM 3, 231–236, APRIL 2006 ªimplicate the cytokine IL-6 and hepatic
STAT3 signaling as regulators of hepatic
glucose handling in response to central
insulin action.
Several important steps in the hypo-
thalamically mediated glycemic response
to insulin have been defined, including
the canonical IRS-protein/phosphatidyl-
inositol (PI) 30-kinase pathway central to
insulin signaling (Gelling et al., 2006). Ad-
ditionally, the activation of ATP-sensitive
potassium (KATP) channels in the baso-
medial hypothalamus (including the arcu-
ate nucleus) by insulin is important for the
central hypoglycemic response to insulin,
as is the integrity of the vagal innervation
of the liver (Obici et al., 2002). Since PI 30-
kinase activates KATP channels (Spans-
wick et al., 1997), a reasonable model
suggests that central insulin regulates
hypothalamic neurons via a PI 30-kinase/
KATP channel-dependent mechanism to
control vagal output to the liver (Figure 1).
Beyond this autonomic input to the liver,
the mechanisms underlying the hepatic
response to central insulin action have
not been well defined, although it is clear
that the suppression of gluconeogenesis
and of the expression of genes that medi-
ate gluconeogenesis (e.g., phosphoenol-
pyruvate carboxykinase; PEPCK) and glu-
cose export from the liver (e.g., glucose
6-phosphatase;G6Pase) represent an im-
portant endpoint in the glucopenic effect
of CNS insulin action. Kasuga and co-
workers previously demonstrated that the
hepatic expression of signal transducer
and activator of transcription-3 (STAT3,
a latent transcription factor that is acti-
vated by tyrosine phosphorylation during
cytokine signaling) is important for proper
glucose homeostasis and the regulation
of PEPCK and G6Pase in the liver (Inoue
et al., 2004), although the precise path-
way regulating hepatic STAT3 in the con-
trol glucose homeostasis was not clear.
In this issue of Cell Metabolism, Inoue
et al. demonstrate that the role of hepatic
STAT3 in glucose homeostasis reflects
the role of STAT3 in mediating a compo-
nent of CNS insulin action upon liver me-
tabolism (Inoue et al., 2006). They show2006 ELSEVIER INC.thatCNS insulin acts via the insulin recep-
tor in brain to mediate the phosphoryla-
tion (activation) of STAT3 in the liver. Im-
portantly, deletion of STAT3 from the
liver worsens the glucose intolerance of
an animal model of hepatic insulin resis-
tance as well as attenuating the ability of
peripheral and ICV insulin to block he-
patic glucose production during a glu-
cose clamp. Indeed, deletion of STAT3
impairs the ability of central and peripher-
ally applied insulin to modulate the ex-
pression of PEPCK and G6Pase. Thus,
hepatic STAT3 participates in the repres-
sion of liver gluconeogenesis and glu-
cose production by CNS insulin action.
But how is STAT3 activated by brain in-
sulin action? IL-6 is a powerful activator of
STAT3 that suppresses the expression of
PEPCK and G6Pase in liver. The Kasuga
group thus examined a role for IL-6 in the
regulation of STAT3 and hepatic glucose
production in response to CNS insulin,
demonstrating that CNS insulin induces
IL-6 expression (likely in Kupffer cells)
within the liver, that interference with IL-6
abrogates hepatic STAT3 activation by in-
sulin, and thatmicenull for IL-6alsoexhibit
impaired suppression of hepatic glucose
production in response to insulin. Thus,
the current work defines a complex path-
way in which CNS insulin action induces
IL-6 expression in hepatic Kupffer cells,
which in turn activates hepatic STAT3 to
participate in the suppression of PEPCK
and G6Pase and the production of glu-
cose by the liver.
As well as providing a first glimpse into
the mechanisms that operate within the
liver to decrease hepatic glucose output
in response to CNS insulin action, the re-
sults of the current study raise a number
of important questions. Perhaps foremost
is whether this IL-6/STAT3 pathway or its
components (for example, the activation
of hepaticSTAT3byothermeans) contrib-
ute to CNS control of glucose homeo-
stasis in response to other important sig-
nals, such as those mediated by leptin
and/or FAs. Itwill also be interesting tode-
termine whether this IL-6/STAT3 pathway
represents an output of the known PI231
P R E V I E W SFigure 1. Pathways linking central insulin signaling to hepatic glucose metabolism
Previous work has defined a pathway in which insulin signaling in the brain suppresses hepatic gluconeogen-
esis and glucose production via the activation of PI 30-kinase and KATP channels (red pathway). These signals
are communicated to the liver via the vagus nerve to suppress hepatic expression of PEPCK and G6Pase and
thus inhibit hepatic glucose output. In this issue of Cell Metabolism, Inoue et al. demonstrate that liver STAT3 is
activated by the CNS actions of insulin and contributes to the regulation of PEPCK and G6Pase expression
and hepatic glucose output (green pathway). This STAT3 response is dependent upon the local production
of IL-6, the expression of which is stimulated (apparently in hepatic Kupffer cells) by CNS insulin action. It
is not yet clear whether this hepatic STAT3-dependent pathway operates downstream of or parallel to the
pathway mediated by the regulation of PI 30-kinase and KATP channels in the CNS.30-kinase/KATP/vagal pathway leading
fromCNS insulinaction to thesuppression
of hepatic gluconeogenesis and glucose
output, or ratherwhether theseareparallel232pathways that each contribute to a com-
mon end. How do the pathways that
suppress hepatic glucose production in
response to insulin, leptin, and FAs inter-sect with those that mediate the response
to hypoglycemia? Whatever the ultimate
answer to these questions, the mecha-
nisms linking the CNS to hepatic metabo-
lismand therefore toglycemiccontrol pro-
vide not only interesting insights into the
physiologic machinery but also important
potential targets for therapeutic inter-
vention in insulin-resistant states.
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